Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Studyopen access
- Lee, Chang Min; Yoo, Moon-Won; Son, Young-Gil; Oh, Sung Jin; Kim, Jong-Han; Kim, Hyoung-Il; Park, Joong-Min; Hur, Hoon; Jee, Ye Seob; Hwang, Sun-Hwi; Jin, Sung-Ho; Lee, Sang Eok; Park, Ji-Ho; Seo, Kyung Won; Park, Sungsoo; Kim, Chang Hyun; Jeong, In Ho; Lee, Han Hong; Choi, Sung Il; Lee, Sang-Il; Kim, Chan Young; Kim, In-Hwan; Son, Myoung-Won; Pak, Kyung Ho; Kim, Sungsoo; Lee, Moon-Soo; Min, Jae-Seok
- Issue Date
- KOREAN GASTRIC CANCER ASSOC
- Gastric cancer; Adjuvant chemotherapy; Disease-free survival
- JOURNAL OF GASTRIC CANCER, v.20, no.2, pp.152 - 164
- Journal Title
- JOURNAL OF GASTRIC CANCER
- Start Page
- End Page
- Purpose: To compare long-term disease-free survival (DFS) between patients receiving tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (CAPOX) adjuvant chemotherapy (AC) for gastric cancer (GC). Materials and Methods: This retrospective multicenter observational study enrolled 983 patients who underwent curative gastrectomy with consecutive AC with S-1 or CAPOX for stage II or III GC at 27 hospitals in Korea between February 2012 and December 2013. We conducted propensity score matching to reduce selection bias. Long-term oncologic outcomes, including DFS rate over 5 years (over-5yr DFS), were analyzed postoperatively. Results: The median and longest follow-up period were 59.0 and 87.6 months, respectively. DFS rate did not differ between patients who received S-i and CAPOX for pathologic stage II (P=0.677) and stage III (P=0.899) GC. Moreover, hazard ratio (HR) for recurrence did not differ significantly between S-1 and CAPOX (reference) in stage II (HR, 1.846; 95% confidence interval [CI], 0.693-4.919; P=0.220) and stage III (HR, 0.942; 95% CI, 0.664-1.337; P=0.738) GC. After adjustment for significance in multivariate analysis, pT (4 vs. 1) (HR, 11.667; 95% CI, 1.595-85.351; P=0.016), pN stage (0 vs. 3) (HR, 2.788; 95% CI, 1.502-5.174; P=0.001), and completion of planned chemotherapy (HR., 2.213; 95% CI, 1.618-3.028; P<0.001) were determined as independent prognostic factors for DFS. Conclusions: S-1 and CAPOX AC regimens did not show significant difference in over-5yr DFS after curative gastrectomy in patients with stage II or III GC. The pT, pN stage, and completion of planned chemotherapy were prognostic factors for GC recurrence.
- Files in This Item
- There are no files associated with this item.
- Appears in
- College of Medicine > Department of Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.